5月21日，ImmunityBio盘中下跌7.89%，报7.418美元/股，成交额5214.07万美元。
消息面上，公司近日密集释放多项利好：与日本BCG实验室签署独家协议引进Tokyo-172卡介苗菌株、获得五项覆盖ANKTIVA联合BCG治疗癌症的美国专利（有效期至少至2035年）、以及在AUA 2026年会上公布Nai+BCG疗法在完全缓解率方面优于Nadofaragene与TAR-200的积极比较数据。尽管基本面利好叠加，股价在催化剂集中兑现后出现回调，成交额放大显示市场存在获利了结压力。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.